poisar

Stocks · News reference

AstraZeneca shares are trading higher after the company and Amgen reported that TEZSPIRE demonstrated meaning improvements in histologic remission and dysphagia in a Phase 3 CROSSING trial for eosinophilic esophagitis.

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AZN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth

    GSK is focusing on newer specialty medicines and vaccines to offset pressure from older products and drive long-term growth. Recent product launches including Blenrep, Jemperli, and Arexvy are expected to become major revenue contributors, with Blenrep anticipated as a key growth driver over 3-4 years. The company has doubled its phase II and III blockbuster-potential assets since 2022 and expects sales exceeding £40 billion by 2031. However, GSK faces significant competition from major pharmaceutical companies and must navigate patent expirations, particularly in HIV.

    GSKAZNMRKSNYGILD